Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 69Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 48Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 35Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Biliary Tract Neoplasms 29Neoplasms 28Neoplasm Metastasis 28Cholangiocarcinoma 26Triple Negative Breast Neoplasms 25Pancreatic Neoplasms 25Ovarian Neoplasms 24Liver Neoplasms 18Head and Neck Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 14Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

durvalumab 1alfatide II 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-Small Cell Lung Cancer NSCLC × durvalumab × Clear all
NCT02879617 2024-01-05

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Academic Thoracic Oncology Medical Investigators Consortium

Phase 2 Completed
47 enrolled 34 charts
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡